Updated Haematological Malignancy Eligibility (data model ...€¦ · Haeamtological malignancies are both broadened and simplified: Such a change would also enable a smoother transition

Updated Haematological Malignancy Eligibility (data model v3.2.0) PAR-GUI-050 v0.1

SOP: QUALITY ASSURANCE AUDITS | Data Quality Assurance 1

Site Participants Document Role Resource for consenters

Document Key PAR-GUI-050 Review Date

Parent SOP/Guide Reference Number

Version 1.0

Document Owner Name

Job title Version Date 29/11/2017

Document Author and Job Title

Dr Kay Lawson Lead GMC Liaison Officer

Status

Document Reviewers and Job Title

Dr Clare Craig Clinical Lead for Cancer Recruitment

Effective Date

Dr Shirley Henderson

Lead for Cancer Molecular Diagnostics

Dr Angela Hamblin

Clinical Lead for Haematology

Amanda O’Neill Director of Clinical Data

Document Approvers and Job Title

Dr Tom Fowler Deputy Chief Scientist

Electronic Signature

Date Approved

Transaction Number

Tom Fowler (Mar 5, 2018)Tom Fowler Mar 5, 2018��*� ��$")��-�).��/$*)��0(� -ѷ��)% !�п.�&�'5р��4�5��#4��у

https://secure.eu1.echosign.com/verifier?tx=CBJCHBCAABAAObdCFnjefT0sckdlHz1dQyDzGFXhyGM4

https://secure.eu1.echosign.com/verifier?tx=CBJCHBCAABAAObdCFnjefT0sckdlHz1dQyDzGFXhyGM4


Contents 1. Document Version History ............................................................................................... 3

2. Document Purpose ........................................................................................................... 3

3. Audience ........................................................................................................................... 3

4. New eligibility criteria ....................................................................................................... 4

5. Data Entry ......................................................................................................................... 5

Appendix A ................................................................................................................................ 6

Myleoproliferative Neoplasms .............................................................................................. 6

Myeloid and lymphoid neoplasms with eosinophilia ........................................................... 7

Myelodysplastic Syndrome / Myeloproliferative Disorders ................................................. 9

Myelodysplastic Syndromes ................................................................................................ 10

Acute Myeloid Leukaemias ................................................................................................. 11

Acute Leukaemias ............................................................................................................... 13

Precursor Lymphoid ............................................................................................................ 14

Mature B Cell ....................................................................................................................... 15

Mature T Cell ....................................................................................................................... 19

Histiocytic and Dendritic Sarcoma ...................................................................................... 21

Post Transplant Lymphoproliferative Disorder ................................................................... 22


1. Document Version History

Version Author Date

approved

Summary of main changes and reasons

1.0 Kay Lawson 29/11/2017 First version

2. Document Purpose Feedback has been received from several GMCs requesting that the eligibility criteria for

Haeamtological malignancies are both broadened and simplified: Such a change would also

enable a smoother transition to a genomic clinical service in future.

In response to this feedback, the eligibility criteria for Haematological malignancies have

therefore been widened with the aim of increasing recruitment. In addition to allowing

more patients with haematological cancers to participate in the project, the increased

number of samples should assist Genomics England cancer analysts with validation of the

cancer structural variant analysis pipelines.

This has resulted in a number of new disease subtypes being approved for inclusion in the

programme in advance of the next update of the data model. Therefore, some disease

specific data items (including some subtypes, tumour markers and staging systems) are not

included in the current version of the data specification (version 3.2.0 of the cancer data

specification) and the frequent widening of tumour eligibility for the programme means it is

possible that not all disease specific data items required for new tumour (sub)types will be

included in the planned update (v3.2.1).

This document is intended to provide guidance as to how to collect data on these new

tumour subtypes where the data model does not, and may not, fully accommodate them.

If you would like to notify us of any specific changes related to these cancers that should be

accommodated in the next update please notify us via the Genomics England Service Desk:

[email protected]

3. Audience This document is aimed at health care professionals involved in the recruitment of patients

with haematological diseases and individuals responsible for providing the relevant patient

data.

mailto:[email protected]


4. New eligibility criteria A summary of the broadened eligibility criteria is given below. Please note these criteria

apply to adults, children, trial (i.e. patients undergoing parallel recruitment into a clinical

trial) and non-trial patients. Patients meeting the following criteria are eligible for

recruitment at both first presentation and relapse; it is not necessary to submit a diagnostic

sample from a patient presenting with relapsed disease although if DNA meeting the

requirements detailed in the current Sample Handling Guidance document

(https://www.genomicsengland.co.uk/information-for-gmc-staff/sample-handling-

guidance/) is available its submission is encouraged.

Eligible:

All patients with a Haematological Malignancy with >40% malignant nuclei for whom

treatment is imminently planned

o Includes all patients with myeloma with >40% CD138+ve cells providing the

cells have undergone an enrichment process (e.g. column sort)

All patients with an Acute Leukaemia as defined by WHO Classification of

haematopoietic and lymphoid tumours (2016) i.e. either >=20% blasts or with a

leukaemia defining genetic abnormality

All patients with Myelodysplastic Syndromes (MDS) with >=5% blasts

Patients with Chronic Myeloid Leukaemia (CML) who meet the following criteria:

o Extreme responders: i.e. those patients who, after 3 months of treatment with a tyrosine kinase inhibitor, have BCR-ABL transcript levels (by RQ-PCR) using International Standards of either <1% (extreme good responder) or >10% (extreme bad responder)

o Present in accelerated or blast phase (i.e. >10% blasts in bone marrow or peripheral blood as determined by morphology)

o Have another cytogenetic abnormality in addition to t(9;22) at diagnosis (NB this criteria excludes patients with their sole cytogenetic abnormality being a variant transcript)

o Progress from chronic phase to accelerated or blast phase

Patients with an unclassified or unknown diagnosis e.g.

Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN)1 overlap syndromes,

‘triple negative Myeloproliferative Neoplasm (defined as no variant detected in JAK2

1 The term Myeloproliferative Neoplasm succeeds Myeloproliferative Disorder (MPD)

https://www.genomicsengland.co.uk/information-for-gmc-staff/sample-handling-guidance/


exon 12 or codon 617, CALR exon 9 or MPL exon 10) or uncertain diagnoses where

the clinical presentation does not fit with the pathological diagnosis

Ineligible:

Patients with Chronic Lymphocytic Lymphoma or another Lymphoproliferative

Disorder for which no treatment is planned i.e. undergoing a watch and wait

management approach

Patients with Myelodysplastic Syndromes with <5% blasts

Patients with stable chronic phase Chronic Myeloid Leukaemia or other

Myeloproliferative Neoplasms

5. Data Entry The majority of subtypes are now eligible for collection. In order to collect any of the eligible

subtypes not enumerated in the data model, use the subtype enumeration ‘other’. Please

ensure the correct specific WHO approved morphology codes are used in these cases

(attached in Appendix A).

Policy Template

Document Key PAR-GUI-050 Version Number 1.0

Author Kay Lawson Issue date

Authorised by Review date

This document is uncontrolled if printed Page 6 of 22

Appendix A

Myleoproliferative Neoplasms

Genomics England category WHO

morphology code

WHO name Notes

other 9875/3 Chronic myelogenous leukaemia, BCR-ABL1 positive

Extreme responders and other special cases eligible as described above

other 9963/3 Chronic neutrophilic leukaemia Eligible if >40% malignant nuclei and about to receive treatment*

other 9950/3 Polycythaemia vera Only eligible in cases of unusual clinical behaviour e.g. progression*

other 9961/3 Primary myelofibrosis Only eligible in cases of unusual clinical behaviour e.g. progression*

other 9962/3 Essential thrombocythaemia Only eligible in cases of unusual clinical behaviour e.g. progression*

other 9964/3 Chronic eosinophilic leukaemia, NOS Eligible if >40% malignant nuclei and about

to receive treatment

other 9975/3 Myeloproliferative neoplasm, unclassified Eligible assuming meets eligibility criteria for

unclassified or unknown diagnosis*

*It is appreciated that the malignant clone will not necessarily have an identifiable morphological phenotype. Myeloproliferative neoplasms are eligible providing 40%

of the nuclei in the sample are within myeloid cells reasonably expected to be involved in the malignant clone.

Policy Template:





Matocytosis


morphology code

WHO name Notes

other 9741/3 Systemic Mastocytosis with an associated haematological neoplasm

Eligible if >40% malignant nuclei and about to

receive treatment

other 9741/3 Aggressive Systemic mastocytosis Eligible if >40% malignant nuclei and about to

receive treatment

other 9742/3 Mast cell leukaemia Eligible if >40% malignant nuclei and about to

receive treatment

other 9740/3 Mast cell sarcoma Eligible if >40% malignant nuclei and about to

receive treatment

Policy Template:





Myeloid and lymphoid neoplasms with eosinophilia


morphology code

WHO name Notes

other 9965/3 Myeloid/lymphoid neoplasms associated with PDGFRA rearrangement


receive treatment

other 9966/3 Myeloid/lymphoid neoplasms associated with PDGFRB rearrangement


receive treatment

other 9967/3 Myeloid/lymphoid neoplasms associated with FGFR1 rearrangement


receive treatment

other 9968/3 Myeloid/lymphoid neoplasms with PCM1-JAK2


receive treatment

Policy Template:





Myelodysplastic Syndrome / Myeloproliferative Disorders


morphology code

WHO name Notes

other 9945/3 Chronic myelomonocytic leukaemia, NOS Eligible if >40% malignant nuclei and about


other 9876/3 Atypical chronic myeloid leukaemia, BCR-ABL1 negative

Eligible if >40% malignant nuclei and about


other 9946/3 Juvenile myelomonocytic leukaemia Eligible if >40% malignant nuclei and about


other 9975/3 Myelodysplastic/Myeloproliferative neoplasm, unclassifiable

Eligible assuming meets eligibility criteria for unclassified or unknown diagnosis

other 9982/3 Myelodysplastic/Myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Eligible if >40% malignant nuclei and about to receive treatment*

*It is appreciated that the malignant clone will not necessarily have an identifiable morphological phenotype. Myeloproliferative neoplasms are eligible providing 40%

of the nuclei in the sample are within myeloid cells reasonably expected to be involved in the malignant clone.

Policy Template:





Myelodysplastic Syndromes


morphology code

WHO name Notes

N/A 9980/3 Myelodysplastic syndrome with single lineage dysplasia

Ineligible as by definition <5% blasts

N/A 9982/3 Myelodysplastic syndrome with with ring sideroblasts and single lineage dysplasia


N/A 9993/3 Myelodysplastic syndrome with with ring sideroblasts and multilineage dysplasia


N/A 9985/3 Myelodysplastic syndrome with multilineage dysplasia


myelodysplastic_syndrome_high_risk 9983/3 Myelodysplastic syndrome with excess blasts

Eligible

N/A 9986/3 Myelodysplastic syndrome with isolated del(5q)


N/A 9989/3 Myelodysplastic syndrome, unclassifiable Ineligible as by definition <5% blasts

N/A 9985/3 Refractory cytopenia of childhood Ineligible as by definition <5% blasts

Policy Template:





Acute Myeloid Leukaemias


morphology code

WHO name Notes

(AML) Acute myeloid Leukaemia 9896/3 Acute myeloid leukaemia, t(8;21)(q22;q22); RUNX1-RUNX1T1

Eligible

(AML) Acute myeloid Leukaemia 9871/3 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

Eligible

(AML) Acute myeloid Leukaemia 9866/3 Acute promyelocytic leukaemia with PML-RARA

Eligible

(AML) Acute myeloid Leukaemia 9897/3 AML with t(9;11)(p22;q23); KMT2A-MLLT3 Eligible

(AML) Acute myeloid Leukaemia 9865/3 Acute myeloid leukaemia with t(6;9)(p23;q34) DEK-NUP214

Eligible

(AML) Acute myeloid Leukaemia 9869/3 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2, MECOM

Eligible

(AML) Acute myeloid Leukaemia 9911/3 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1

Eligible

AML) Acute myeloid Leukaemia 9912/3 AML with BCR-ABL1 Eligible

(AML) Acute myeloid Leukaemia 9877/3 AML with mutated NPM1 Eligible

(AML) Acute myeloid Leukaemia 9878/3 AML with biallelic mutation of CEBPA Eligible

AML) Acute myeloid Leukaemia 9879/3 AML with mutated RUNX1 Eligible

(AML) Acute myeloid Leukaemia 9895/3 AML with myelodysplasia-related changes Eligible

(AML) Acute myeloid Leukaemia 9920/3 Therapy-related myeloid neoplasms Eligible

(AML) Acute myeloid Leukaemia 9861/3 Acute myeloid leukaemia, NOS Eligible

(AML) Acute myeloid Leukaemia 9872/3 AML minimal differentiation Eligible

(AML) Acute myeloid Leukaemia 9873/3 AML without maturation Eligible

(AML) Acute myeloid Leukaemia 9874/3 AML with maturation Eligible

(AML) Acute myeloid Leukaemia 9867/3 Acute myelomonocytic leukaemia Eligible

Policy Template:





(AML) Acute myeloid Leukaemia 9891/3 Acute monoblastic and monocytic leukaemia Eligible

(AML) Acute myeloid Leukaemia 9840/3 Pure erythroid leukaemia Eligible

(AML) Acute myeloid Leukaemia 9910/3 Acute megakaryoblastic leukaemia Eligible

(AML) Acute myeloid Leukaemia 9870/3 Acute basophilic leukaemia Eligible

(AML) Acute myeloid Leukaemia 9931/3 Acute panmyelosis with myelofibrosis Eligible

(AML) Acute myeloid Leukaemia 9930/3 Myeloid sarcoma Eligible

(AML) Acute myeloid Leukaemia 9898/1 Transient abnormal Myelopoiesis associated with Down syndrome

Eligible if >5% blasts

(AML) Acute myeloid Leukaemia 9898/3 Myeloid leukaemia associated with Down Syndrome

Eligible

(AML) Acute myeloid Leukaemia 9727/3 Blastic plasmacytoid dendritic cell neoplasm Eligible

Policy Template:





Acute Leukaemias


morphology code

WHO name Notes

Other 9801/3 Acute undifferentiated leukaemia Eligible

Other 9806/3 Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR-ABL1

Eligible

Other 9807/3 Mixed phenotype acute leukaemia with t(v;11q23); KMT2A-rearranged

Eligible

Other 9808/3 Mixed phenotype acute leukaemia, B/myeloid, NOS

Eligible

Other 9809/3 Mixed phenotype acute leukaemia, T/myeloid, NOS

Eligible

Other NO CODE Mixed phenotype acute leukaemia, NOS, rare types

Eligible

Other NO CODE Acute leukaemias of ambiguous lineage, NOS

Eligible

Policy Template:





Precursor Lymphoid


morphology code

WHO name Notes

(ALL) Acute lymphoblastic leukaemia

9811/3 B-lymphoblastic leukaemia/lymphoma, NOS Eligible


9812/3 B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2);BCR-ABL1

Eligible


9813/3 B-lymphoblastic leukaemia/lymphoma with t(v;11q23);KMT2A-rearranged

Eligible


9814/3 B lymphoblastic leukaemia/lymphoma t(12;21)(p13;q22); ETV6-RUNX1

Eligible


9815/3 B-lymphoblastic leukaemia/lymphoma with hyperdiploidy

Eligible


9816/3 B-lymphoblastic leukaemia/lymphoma with hypodiploidy (hypodiploid ALL)

Eligible


9817/3 B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32);IGH/IL3

Eligible

(ALL) Acute lymphoblastic leukaemia 9818/3

B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1

Eligible


B-lymphoblastic leukaemia/lymphoma, BCR-ABL1-like

Eligible


B-lymphoblastic leukaemia/lymphoma with iAMP21

Eligible


9837/3 T-lymphoblastic leukaemia/lymphoma Eligible


9837/3 Early T-cell precursor lymphoblastic leukaemia/lymphoma

Eligible


NO CODE NK-lymphoblastic leukaemia/lymphoma Eligible

Policy Template:





Mature B Cell


morphology code

WHO name Notes

Chronic lymphocytic leukaemia 9823/3 Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma

Eligible if >40% malignant nuclei and about to receive treatment

Chronic lymphocytic leukaemia 9833/3 B-cell prolymphocytic leukaemia Eligible if >40% malignant nuclei and about to receive treatment

Non-Hodgkins B cell lymphoma low / moderate grade

9689/3 Splenic marginal zone B-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment


9940/3 Hairy cell leukaemia Eligible if >40% malignant nuclei and about to receive treatment


9591/3 Splenic B-cell lymphoma/leukaemia, unclassifiable



9591/3 Splenic diffuse red pulp small B-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment


9591/3 Hairy cell leukaemia variant Eligible if >40% malignant nuclei and about to receive treatment


9671/3 Lymphoplasmacytic lymphoma Eligible if >40% malignant nuclei and about to receive treatment


9761/3 Waldenstrom macroglobulinemia Eligible if >40% malignant nuclei and about to receive treatment

Other 9762/3 Alpha heavy chain disease Eligible if >40% malignant nuclei and about to receive treatment

Other 9762/3 Gamma heavy chain disease Eligible if >40% malignant nuclei and about to receive treatment

Other 9762/3 Mu heavy chain disease Eligible if >40% malignant nuclei and about to receive treatment

Multiple myeloma 9732/3 Plasma cell myeloma See eligibility criteria

Policy Template:





Multiple myeloma 9731/3 Solitary Plasmacytoma of bone Eligible if >40% malignant nuclei and about to receive treatment

Multiple myeloma 9734/3 Extraosseous Plasmacytoma Eligible if >40% malignant nuclei and about to receive treatment


9699/3 Extranodal marginal zone lymphoma of mucosa- associated lymphoid tissue (MALT lymphoma)



9699/3 Nodal Marginal zone lymphoma Eligible if >40% malignant nuclei and about to receive treatment


9699/3 Paediatric Nodal Marginal zone lymphoma Eligible if >40% malignant nuclei and about to receive treatment


9690/3 Follicular lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Non-Hodgkins B cell lymphoma low / moderate grade 9695/3 Duodenal-type follicular lymphoma


Non-Hodgkins B cell lymphoma low / moderate grade 9690/3 Testicular follicular lymphoma



9690/3 Paediatric-type follicular lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Other 9698/3 Large B-cell lymphoma with IRF4 rearrangement



9597/3 Primary Cutaneous follicle centre lymphoma Eligible if >40% malignant nuclei and about to receive treatment


9673/3 Mantle cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 Diffuse Large B-cell lymphoma (DLBCL), NOS Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 Diffuse Large B-cell lymphoma (DLBCL), Germinal centre B-cell subtype


Policy Template:





Diffuse large B-cell lymphoma 9680/3 Diffuse Large B-cell lymphoma (DLBCL), activated B-cell subtype


Diffuse large B-cell lymphoma 9688/3 T-cell histiocyte rich large B-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 Primary DLBCL of the CNS Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 Primary Cutaneous DLBCL, leg type Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 EBV positive DLBCL, NOS Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 DLBCL associated with chronic inflammation Eligible if >40% malignant nuclei and about to receive treatment

Other 9766/3 Lymphomatoid granulomatosis, grade 3 Eligible if >40% malignant nuclei and about to receive treatment

Mediastinal B-cell lymphoma 9679/3 Primary Mediastinal (thymic) large B-cell lymphoma


Diffuse large B-cell lymphoma 9712/3 Intravascular large B-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9737/3 ALK positive large B-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9735/3 Plasmablastic lymphoma Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9678/3 Primary effusion lymphoma Eligible if >40% malignant nuclei and about to receive treatment - amber

Other 9738/3 Multicentric Castleman Disease Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9738/3 HHV8-positive DLBCL, NOS Eligible if >40% malignant nuclei and about to receive treatment - amber

Policy Template:





Other 9687/3 Burkitt lymphoma, NOS Eligible if >40% malignant nuclei and about to receive treatment

Other 9687/3 Burkitt lymphoma with 11q aberration Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9680/3 High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements


Diffuse large B-cell lymphoma 9680/3 High grade B-cell lymphoma, NOS Eligible if >40% malignant nuclei and about to receive treatment

Diffuse large B-cell lymphoma 9596/3 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma


Policy Template:





Mature T Cell


morphology code

WHO name Notes

t_cell_lymphoma 9834/3 T-cell prolymphocytic leukaemia Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9831/3 T-cell large granular lymphocytic leukaemia Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9831/3 Chronic lymphoproliferative disorder of NK cells


t_cell_lymphoma 9948/3 Aggressive NK cell leukaemia Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9724/3 Systemic EBV-positive T-cell lymphoma of childhood


t_cell_lymphoma 9827/3 Adult T-cell leukaemia/lymphoma Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9719/3 Extranodal NK/T-cell lymphoma, nasal type Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9717/3 Enteropathy-associated T-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9717/3 Monomorphic epitheliotropic intestinal T-cell lymphoma


t_cell_lymphoma 9716/3 Hepatosplenic T-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9708/3 Subcutaneous panniculitis-like T-cell lymphoma


t_cell_lymphoma 9700/3 Mycosis fungoides Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9701/3 Sézary syndrome Eligible if >40% malignant nuclei and about to receive treatment

Policy Template:





t_cell_lymphoma 9718/3 Primary cutaneous anaplastic large cell lymphoma


t_cell_lymphoma 9726/3 Primary cutaneous gamma-delta T-cell lymphoma


t_cell_lymphoma 9709/3 Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma


t_cell_lymphoma 9709/3 Primary cutaneous acral CD8-positive T-cell lymphoma


t_cell_lymphoma 9702/3 Peripheral T-cell lymphoma, NOS Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9705/3 Angioimmunoblastic T-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9702/3 Follicular T-cell lymphoma Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9702/3 Nodal peripheral T-cell lymphoma with T follicular helper phenotype


t_cell_lymphoma 9714/3 Anaplastic large cell lymphoma, ALK positive Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9715/3 Anaplastic large cell lymphoma, ALK negative Eligible if >40% malignant nuclei and about to receive treatment

t_cell_lymphoma 9715/3 Breast implant-associated anaplastic large cell lymphoma


Policy Template:





Histiocytic and Dendritic Sarcoma


morphology code

WHO name Notes

Other 9755/3 Histiocytic sarcoma Eligible if >40% malignant nuclei and about to receive treatment

Other 9751/3 Langerhans cell histiocytosis, disseminated Eligible if >40% malignant nuclei and about to receive treatment

Other 9756/3 Langerhans cell sarcoma Eligible if >40% malignant nuclei and about to receive treatment

Other 9757/3 Interdigitating dendritic cell sarcoma Eligible if >40% malignant nuclei and about to receive treatment

Other 9758/3 Follicular dendritic cell sarcoma Eligible if >40% malignant nuclei and about to receive treatment

Other 9759/3 Fibroblastic reticular cell tumor Eligible if >40% malignant nuclei and about to receive treatment

Other 9757/3 Indeterminate dendritic cell tumour Eligible if >40% malignant nuclei and about to receive treatment

Other NO CODE Disseminated juvenile xanthogranuloma Eligible if >40% malignant nuclei and about to receive treatment

Other 9749/3 Erdheim – Chester disease Eligible if >40% malignant nuclei and about to receive treatment

Policy Template:





Post Transplant Lymphoproliferative Disorder


morphology code

WHO name Notes

other

Classified as per lymphoma to which they correspond

Monomorphic PTLD Eligible if >40% malignant nuclei and about to receive treatment

other 9650/3 Classical Hodgkin lymphoma type PTLD

Eligible if >40% malignant nuclei and about to receive treatment – unlikely that any HD will have >40% Reed-Sternberg cells

Documents

Updated Haematological Malignancy Eligibility (data model ...€¦ · Haeamtological malignancies are both broadened and simplified: Such a change would also enable a smoother transition